Sacral Neuromodulation for Male Overactive Bladder.

A clinical trial, NCT06511141, is currently underway to assess the effectiveness and safety of the Axonics SNM System for treating overactive bladder in male patients who have undergone prostate cancer treatment or surgical intervention for benign prostatic hyperplasia. The trial aims to evaluate the device's impact on quality of life and reduction in urinary urgency incontinence episodes. The study, conducted by Axonics, Inc., plans to enroll 120 male participants and is expected to be completed by June 30, 2026. This document provides information on the study's objectives, eligibility criteria, and contact details for those interested in participating. [Extracted from the article]